Login / Signup

Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity.

Peng ZhangFang SunCaroline TsaoSijun LiuPriyesh JainAndrew SinclairHsiang-Chieh HungTao BaiKan WuShaoyi Jiang
Published in: Proceedings of the National Academy of Sciences of the United States of America (2015)
Advances in protein therapy are hindered by the poor stability, inadequate pharmacokinetic (PK) profiles, and immunogenicity of many therapeutic proteins. Polyethylene glycol conjugation (PEGylation) is the most successful strategy to date to overcome these shortcomings, and more than 10 PEGylated proteins have been brought to market. However, anti-PEG antibodies induced by treatment raise serious concerns about the future of PEGylated therapeutics. Here, we demonstrate a zwitterionic polymer network encapsulation technology that effectively enhances protein stability and PK while mitigating the immune response. Uricase modified with a comprehensive zwitterionic polycarboxybetaine (PCB) network exhibited exceptional stability and a greatly prolonged circulation half-life. More importantly, the PK behavior was unchanged, and neither anti-uricase nor anti-PCB antibodies were detected after three weekly injections in a rat model. This technology is applicable to a variety of proteins and unlocks the possibility of adopting highly immunogenic proteins for therapeutic or protective applications.
Keyphrases
  • immune response
  • protein protein
  • binding protein
  • small molecule
  • stem cells
  • toll like receptor
  • combination therapy
  • network analysis
  • wound healing